Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

77
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
77
Skin Cancer01:30

Skin Cancer

5.1K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Daridorexant: First Approval.

Drugs·2022
Same author

Gefapixant: First Approval.

Drugs·2022
Same author

Daridorexant: First Approval.

Drugs·2022
Same author

Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.

Targeted oncology·2022
Same author

Envafolimab: First Approval.

Drugs·2022
Same author

Correction to: Avatrombopag: A Review in Thrombocytopenia.

Drugs·2021
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Nov 16, 2025

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.2K

Setmelanotide: First Approval.

Anthony Markham1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|February 27, 2021
PubMed
Summary
This summary is machine-generated.

Setmelanotide is a new MC4 receptor agonist approved for obesity caused by POMC, PCSK1, or LEPR deficiencies. This drug targets rare genetic disorders, offering a new treatment for chronic weight management in eligible patients.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.7K
Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

18.5K

Related Experiment Videos

Last Updated: Nov 16, 2025

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.2K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.7K
Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

18.5K

Area of Science:

  • Pharmacology
  • Genetics
  • Endocrinology

Background:

  • Obesity is a complex condition with various genetic causes.
  • Deficiencies in the melanocortin-4 receptor (MC4R) pathway, such as POMC, PCSK1, and LEPR deficiencies, lead to severe obesity.
  • Current treatment options for these rare genetic obesity types are limited.

Purpose of the Study:

  • To summarize the development milestones of setmelanotide.
  • To highlight the drug's approval for specific genetic obesity types.
  • To provide an overview of setmelanotide's mechanism of action and therapeutic potential.

Main Methods:

  • Review of preclinical and clinical studies on setmelanotide.
  • Analysis of regulatory submissions and approvals.
  • Summary of the drug's pharmacological profile.

Main Results:

  • Setmelanotide, a selective MC4R agonist, has demonstrated efficacy in treating obesity due to POMC, PCSK1, and LEPR deficiencies.
  • The drug received FDA approval for chronic weight management in patients aged 6 years and older with these specific genetic conditions.
  • European Medicines Agency granted PRIME designation for obesity and hunger control in MC4R pathway deficiencies.

Conclusions:

  • Setmelanotide represents a significant advancement in targeted therapy for rare genetic obesity disorders.
  • The drug's development milestones underscore the progress in understanding and treating MC4R pathway-related obesity.
  • Further research and development are ongoing for other rare genetic conditions associated with obesity.